Cantor Fitzgerald Reiterates Overweight Rating on Arvinas Inc. (ARVN) Sep 18, 2025 06:52AM
Cantor Fitzgerald says 15% of biotech companies down 40% or more Mar 17, 2025 07:06AM
Companies with NDRs 7/14 Jul 14, 2021 07:25AM
Companies with NDRs 6/29 Jun 29, 2021 07:45AM
Arvinas Inc. (ARVN) PT Raised to $121 at Cantor Fitzgerald Jan 5, 2021 06:51AM


Dec 28, 2020 04:30PM Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
Dec 28, 2020 04:30PM Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
Dec 16, 2020 06:14AM Arvinas Inc. (ARVN) Prices 5.714M Share Common Offering at $70/Sh
Dec 15, 2020 08:34PM Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
Dec 15, 2020 08:34PM Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
May 29, 2020 12:24PM Arvinas (ARVN) Weakness a Buying Opportunity - Cantor Fitzgerald
May 14, 2020 03:43PM Buy Arvinas (ARVN) on Weakness - Cantor Fitzgerald
Apr 21, 2020 07:52AM Arvinas Inc. (ARVN) Could Triple Beginning With ASCO Data - Cantor Fitzgerald
Apr 14, 2020 06:59AM Cantor Fitzgerald Reiterates Overweight Rating on Arvinas Inc. (ARVN)
Dec 20, 2019 06:57AM Arvinas Inc's (ARVN) Opportunity in PROTAC is at the Beginning, PT Raised to $75 at Cantor Fitzgerald
Aug 6, 2019 06:39AM UPDATE: Cantor Fitzgerald Starts Arvinas Inc. (ARVN) at Overweight